Publications

Selected Publications

2025

Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12. 
Troester S, Eder T, Wukowits N, Piontek M, Fernández-Pernas P, Schmoellerl J, Haladik B, Manhart G, Allram M, Maurer-Granofszky M, Scheidegger N, Nebral K, Superti-Furga G, Meisel R, Bornhauser B, Valent P, N. Dworzak M, Zuber J, Boztug K & Grebien F. 
Nat Comm.; May 2025. available at https://www.nature.com/articles/s41467-025-59930-9

DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.
Kaya F, Bewicke-Copley F, Miettinen JJ, Casado P, Leddy E, Deniz Ö, Lavallée VP, Philippe C, Zheng J, Grebien F, Khan N, Krizsán S, Saad J, Nolin-Lapalme A, Hébert J, Lemieux S, Audemard E, Matthews J, Grantham M, Di Bella D, Wennerberg K, Parsons A, Gribben J, Cavenagh JD, Freeman SD, Bödör C, Sauvageau G, Wang J, Llamas-Sillero P, Cazier JB, Taussig DC, Bonnet D, Cutillas PR, Heckman CA, Fitzgibbon J, Rouault-Pierre K, Rio-Machin A.
Leukemia. 2025 June; available at https://www.nature.com/articles/s41375-025-02593-8

Clec12a is required for the pathogenesis of NUP98::NSD1 AML.
Mohanty S, Charles Cano F, Gabdoulline R, Lai CK, Othman B, Sudarsanam H, Eder T, Grebien F, Lipka DB, Henschler R, Heuser M.
Blood Adv. 2025 May Available at https://doi.org/10.1182/bloodadvances.2024015739

Deciphering the code of resistance: a genomic and transcriptomic exploration of the Cystoisospora suis Holland-I strain. 
Cruz-Bustos T, Eder T, Ruttkowski B, Joachim A. 
Sci Rep.; February 2025. available at https://doi.org/10.1038/s41598-025-89372-8

2024

Off-Target Inhibition of Human Dihydroorotate Dehydrogenase (hDHODH) Highlights Challenges in the Development of Fat Mass and Obesity-Associated Protein (FTO) Inhibitors.Tarullo M, Fernandez Rodriguez G, Iaiza A, Venezia S, Macone A, Incocciati A, Masciarelli S, Marchioni M, Giorgis M, Lolli ML, Fornaseri F, Proietti L, Grebien F, Rosignoli S, Paiardini A, Rotili D, Mai A, Bochenkova E, Caflisch A, Fazi F, Fatica A.ACS Pharmacol Transl Sci. 2024 November, available at https://pubs.acs.org/doi/10.1021/acsptsci.4c00533

Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma.
Pölöske D, Sorger H, Schönbichler A, de Araujo ED, Neubauer HA, Orlova A, Timonen SH, Abdallah DI, Ianevski A, Kuusanmäki H, Surbek M, Heyes E, Eder T, Wagner C, Suske T, Metzelder ML, Bergmann M, Dahlhoff M, Grebien F, Fleck R, Pirker C, Berger W, Hadzijusufovic E, Sperr WR, Kenner L, Valent P, Aittokallio T, Herling M, Mustjoki S, Gunning PT, Moriggl R.
Hemasphere; November 2024. available at https://onlinelibrary.wiley.com/doi/10.1002/hem3.70001  

The adsorption of drugs on nanoplastics has severe biological impact.
Dick L, Batista PR, Zaby P, Manhart G, Kopatz V, Kogler L, Pichler V, Grebien F, Bakos V, Plósz BG, Kolev NZ, Kenner L, Kirchner B, Hollóczki O.
Sci Rep. 2024 October, available at https://www.nature.com/articles/s41598-024-75785-4

NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities.
Rasouli M, Troester S, Grebien F, Goemans BF, Zwaan CM, Heidenreich O.
Hemasphere; September 2024. available at https://onlinelibrary.wiley.com/doi/10.1002/hem3.70013

RNA sequestration in P-bodies sustains myeloid leukaemia.
Kodali S, Proietti L, Valcarcel G, López-Rubio AV, Pessina P, Eder T, Shi J, Jen A, Lupión-Garcia N, Starner AC, Bartels MD, Cui Y, Sands CM, Planas-Riverola A, Martínez A, Velasco-Hernandez T, Tomás-Daza L, Alber B, Manhart G, Mayer IM, Kollmann K, Fatica A, Menendez P, Shishkova E, Rau RE, Javierre BM, Coon J, Chen Q, Van Nostrand EL, Sardina JL, Grebien F, Di Stefano B.
Nature cell biology; August 2024. available at https://www.nature.com/articles/s41556-024-01489-6

Differential regulation of mitochondrial uncoupling protein 2 in cancer cells.
Beikbaghban T, Proietti L, Ebner J, Sango R, Rattei T, Weichhart T, Grebien F, Sternberg F, Pohl EE.
Biochim Biophys Acta Bioenerg. 2024 November, available at https://doi.org/10.1016/j.bbabio.2024.149486

A novel function of STAT3β in suppressing interferon response improves outcome in acute myeloid leukemia.
Edtmayer S, Witalisz-Siepracka A, Zdársky B, Heindl K, Weiss S, Eder T, Dutta S, Graichen U, Klee S, Sharif O, Wieser R, Győrffy B, Poli V, Casanova E, Sill H, Grebien F, Stoiber.
Cell death & disease; May 2024. available at https://www.nature.com/articles/s41419-024-06749-9

Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.
Suske T, Sorger H, Manhart G, Ruge F, Prutsch N, Zimmermann MW, Eder T, Abdallah DI, Maurer B, Wagner C, Schönefeldt S, Spirk K, Pichler A, Pemovska T, Schweicker C, Pölöske D, Hubanic E, Jungherz D, Müller TA, Aung MMK, Orlova A, Pham HTT, Zimmel K, Krausgruber T, Bock C, Müller M, Dahlhoff M, Boersma A, Rülicke T, Fleck R, de Araujo ED, Gunning PT, Aittokallio T, Mustjoki S, Sanda T, Hartmann S, Grebien F, Hoermann G, Haferlach T, Staber PB, Neubauer H, Look AT, Herling M, Moriggl R.
J Clin Investigation; April 2024. available at https://doi.org/10.1172/JCI168536

2023

TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.
Heyes E, Wilhemson AS, Wenzel A, Manhart G, Eder T, Schuster MB, Rzepa E, Pundhir S, D’altri T, Frank A, Gentil C, Woessmann J, Schoof EM, Meggendorfer M, Schwaller J, Haferlach T, Grebien F, Porse BT.
Nat Commun.; October 2023. available at https://doi.org/10.1038/s41467-023-41927-x

ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia.
Ebner J, Schmoellerl J, Piontek M, Manhart G, Troester S, Carter B, Neubauer H, Moriggl R, Szakács G, Zuber J, Köcher T, Andreeff M, Sperr W, Valent P, Grebien F.
Nat Commun.; September 2023. available at https://doi.org/10.1038/s41467-023-41229-2

The Intricacies of Inflammatory Bowel Disease: A Preliminary Study of Redox Biology in Intestinal Organoids.
Csukovich G, Huainig J, Troester S, Pratscher B, Burgener IA.
Organoids; September 2023. available at https://doi.org/10.3390/organoids2030012

The MLL–Menin Interaction is a Therapeutic Vulnerability in NUP98-rearranged AML.
Rasouli M, Blair H, Troester S, Szoltysek K, Cameron R, Ashtiani M, Krippner-Heidenreich A, Grebien F, McGeehan G, Zwaan CM, Heidenreich O.
Hemasphere; August 2023. available at https://doi.org/10.1097/HS9.0000000000000935

Histone Variants and Their Chaperones in Hematological Malignancies.
Kirkiz E, Meers O, Grebien F, Buschbeck M.
Hemasphere; July 2023. available at https://doi.org/10.1097/HS9.0000000000000927

Biomolecular Condensates in Myeloid Leukemia: What Do They Tell Us?
Jevtic Z, Allram M, Grebien F, Schwaller J.
Hemasphere; June 2023. available at https://doi.org/10.1097/HS9.0000000000000923

SBNO2 is a critical mediator of STAT3-driven hematological malignancies.
Brandstoetter T, Schmoellerl J, Grausenburger R, Kollmann S, Doma E, Huuhtanen J, Klampfl T, Eder T, Grebien F, Hoermann G, Zuber J, Mustjoki S, Maurer B, Sexl V.
Blood; April 2023. Online ahead of print. available at https://doi.org/10.1182/blood.2022018494

Antiviral immune response reveals host-specific virus infections in natural ant populations.
Viljakainen L, Fürst MA, Grasse AV, Jurvansuu J, Oh J, Tolonen L, Eder T, Rattei T, Cremer S.
Front Microbiol.; March 2023. available at https://doi.org/10.3389/fmicb.2023.1119002

EVI1 drives leukemogenesis through aberrant ERG activation.
Schmoellerl J, Barbosa IAM, Minnich M, Andersch F, Smeenk L, Havermans M, Eder T, Neumann T, Jude J, Fellner M, Ebert A, Steininger M, Delwel R, Grebien F, Zuber J.
Blood; February 2023. available at https://doi.org/10.1182/blood.2022016592

2022

Arrayed CRISPR/Cas9 Screening for the Functional Validation of Cancer Genetic Dependencies.
Proietti L, Manhart G, Heyes E, Troester S, Grebien F.
Bio Protoc.; December 2022. available at https://doi.org/10.21769/BioProtoc.4577

Decoding molecular programs in melanoma brain metastases.
Radke J, Schumann E, Onken J, Koll R, Acker G, Bodnar B, Senger C, Tierling S, Möbs M, Vajkoczy P, Vidal A, Högler S, Kodajova P, Westphal D, Meier F, Heppner F, Kreuzer-Redmer S, Grebien F, Jürchott K, Redmer T.
Nat Commun.; November 2022. available at https://doi.org/10.1038/s41467-022-34899-x

Identification of CD4+ T cells with T follicular helper cell characteristics in the pig.
Hoog A, Villanueva-Hernández S, Adib Razavi M, van Dongen K, Eder T, Piney L, Chapat L, de Luca K, Grebien F, Mair KH, Gerner W.
Dev. Comp Immunology; September 2022, available at https://doi.org/10.1016/j.dci.2022.104462

A Journey Into the Unknown: PhD Students in a European Training Network on Age-related Changes in Hematopoiesis Conduct Their Project During a Global Pandemic
Pitsillidou C, Alonso-Rubido S, Ávila-Ávila A, Romero-Mulero MC, Labedz A, Oikonomou A, Proietti L, Psychoyiou ME, Tellez-Quijorna C, Hillary M, Fasouli ES, Fernández-Rodríguez G, Giner-Laguarda N, Skinder N, Taroni C, Strouboulis J, Katsantoni E, Ronchi AE
Hemasphere; August 2022, available at https://doi.org/10.1097/HS9.0000000000000763

Increasing test specificity without impairing sensitivity: lessons learned from SARS-CoV-2 serology.
Perkmann T, Koller T, Perkmann-Nagele N, Ozsvar-Kozma M, Eyre D, Matthews P, Bown A, Stoesser N, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S, Aletaha D, Sieghart D, Quehenberger P, Marculescu R, Mucher P, Radakovics A, Klausberger M, Duerkop M, Holzer B, Hartmann B, Strassl R, Leitner G, Grebien F, Gerner W, Grabherr R, Wagner OF, Binder CJ, Haslacher H.
J Clin Pathol.; August 2022, available at https://doi.org/10.1136/jcp-2022-208171

Comprehensive assessment of differential ChIP-seq tools guides optimal algorithm selection.
Eder, T, Grebien, F.
Genome Biol.; May 2022, available at https://doi.org/10.1186/s13059-022-02686-y

Designed SARS-CoV-2 receptor binding domain variants form stable monomers.
Klausberger M, Kienzl NF, Stadlmayr G, Grünwald-Gruber C, Laurent E, Stadlbauer K, Stracke F, Vierlinger K, Hofner M, Manhart G, Gerner W, Grebien F, Weinhäusel A, Mach L, Wozniak-Knopp G.
Biotechnol J.; May 2022, available at https://doi.org/10.1002/biot.202100422

2021

Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness.
Grandits AM, Nguyen CH, Schlerka A, Hackl H, Sill H, Etzler J, Heyes E, Stoiber D, Grebien F, Heller G, Wieser R.
Leukemia; October 2021, available at https://www.nature.com/articles/s41375-021-01224-2.

Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter
van der Kouwe E, Heller G, Czibere A, Pulikkan JA, Agreiter C, Castilla LH, Delwel R, Di Ruscio A, Ebralidze AK, Forte M, Grebien F, Heyes E, Kazianka L, Klinger J, Kornauth C, Le T, Lind K, Inês Amorim Monteiro Barbosa, Pemovska T, Pichler AS, Schmolke AS, Schweicker CM, Sill H, Sperr WR, Spittler A, Surapally S, Trinh BQ, Valent P, Vanura K, Welner RS, Zuber J, Tenen DG, Staber PB
Blood; October 2021, available at https://doi.org/10.1182/blood.2020008971

Impact of Specific N-Glycan Modifications on the Use of Plant-Produced SARS-CoV-2 Antigens in Serological Assays.
Schwestka J, König-Beihammer J, Shin YJ, Vavra U, Kienzl NF, Grünwald-Gruber C, Maresch D, Klausberger M, Laurent E, Stadler M, Manhart G, Huber J, Hofner M, Vierlinger K, Weinhäusel A, Swoboda I, Binder CJ, Gerner W, Grebien F, Altmann F, Mach L, Stöger E, Strasser R.
Front Plant Sci.; September 2021, available at https://www.frontiersin.org/articles/10.3389/fpls.2021.747500/full.

Discovery of a Non-Nucleoside SETD2 Methyltransferase Inhibitor against Acute Myeloid Leukemia
Bajusz D†, Bognár Z†, Ebner J†, Grebien F, Keserű GM
Int. J. Mol. Sci.; September 2021, available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471172/.

Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML
Heyes E, Schmidt L, Manhart G, Eder T, Proietti L, Grebien F.
Leukemia; September 2021, available at https://www.nature.com/articles/s41375-021-01169-6

Exploring protein hotspots by optimized fragment pharmacophores
Bajusz D, Wade WS, Satała G, Bojarski AJ, Ilaš J, Ebner J, Grebien F, Papp H, Jakab F, Douangamath A, Fearon D, von Delft F, Schuller M, Ahel I, Wakefield A, Vajda S, Gerencsér J, Pallai P & Keserű GM
Nature Communications; May 2021, available at https://www.nature.com/articles/s41467-021-23443-y

Regulation of the Mitochondrion-Fatty Acid Axis for the Metabolic Reprogramming of Chlamydia trachomatis during Treatment with β-Lactam Antimicrobials
Shima K , Kaufhold I, Eder T , Käding N, Schmidt N, Ogunsulire IM, Deenen R, Köhrer K, Friedrich D, Isay SE, Grebien F, Klinger M, Richer BC, Günther UL, Deepe Jr GS , Rattei T, Rupp J.
mBio; March 2021, available at https://mbio.asm.org/content/12/2/e00023-21.long

Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions
Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, Kollmann K, Lion T, Virgolini I, Winter G, Hantschel O, Kenner L, Zuber J, Grebien F, Moriggl R, Hoermann G, Hermine O, Andreeff M, Bock C, Mughal T,Constantinescu SN, Kralovics R, Sexl V, Skoda R, Superti-Furga G,4 and Jäger U.
Hemasphere, February 2021, available at https://pubmed.ncbi.nlm.nih.gov/33623882/

Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression
Terlecki-Zaniewicz S, Humer T, Eder T, Schmoellerl J, Heyes E, Manhart G, Kuchynka N, Parapatics K, Liberante FG, Müller AC, Tomazou EM, Grebien F.
Nature Structural & Molecular Biology; January 2021, available at https://nature.com/articles/s41594-020-00550-w

2020

STAT5 is required for lipid breakdown and beta-adrenergic responsiveness of brown adipose tissue
Kaltenecker D, Spirk K, Ruge F, Grebien F, Herling M, Rupprecht A, Kenner L, Pohl EE, Mueller KM, Moriggl R.
Mol Metab. 2020 Oct;40:101026. doi: 10.1016/j.molmet.2020.101026. available at https://pubmed.ncbi.nlm.nih.gov/32473405/

Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia
Mohanty S, Jyotsana N, Sharma A, Kloos A, Gabdoulline R, Othman B, Lai CK, Schottmann R, Mandhania M, Schmoellerl J, Grebien F, Ramsay E, Thomas A, Vornlocher HP, Ganser A, Thol F, Heuser M.
Cancers (Basel). 2020 Sep 26;12(10). doi: 10.3390/cancers12102766. available at https://pubmed.ncbi.nlm.nih.gov/32993115/

CDK6 is an essential direct target of NUP98-fusion proteins in acute myeloid leukemia
Schmoellerl J, Barbosa I, Eder T, Brandstoetter T, Schmidt L, Maurer B, Troester S, Pham HTT, Sagarajit M, Ebner J, Manhart G, Aslan E, Terlecki-Zaniewicz S, Van der Veen C, Hoermann G, Duployez N, Petit A, Lapillonne H, Puissant A, Itzykson RA, Moriggl RH, Heuser M, Meisel R, Valent P, Sexl V, Zuber J, Grebien F.
Blood; April 2020, pii: blood.2019003267, available at https://www.ncbi.nlm.nih.gov/pubmed/32344427

Gain‐of‐Function Effects of N‐Terminal CEBPA Mutations in Acute Myeloid Leukemia
Schmidt L, Heyes E, Grebien F.
BioEssays; January 2020, 1900178, available at https://pubmed.ncbi.nlm.nih.gov/31867767/

HBO1 is required for the maintenance of leukaemia stem cells
MacPherson L, Anokye J, Yeung MM, Lam EYN, Chan Y-C, Weng C-F, Yeh P, Knezevic K, Butler MS, Hoegl A, Chan K-L, Burr ML, Gearing LJ, Willson T, Liu J, Choi J, Yang Y, Bilardi RA, Falk H, Nguyen N, … , Grebien F, Dawson SJ, Street IP, Monahan BJ, Burns CJ, Choudhary , Blewitt ME, Voss AK, Thomas T & Dawson MA.
Nature; January 2020, 577: 266–270, available at https://pubmed.ncbi.nlm.nih.gov/31827282/ 

High activation of STAT5A drives peripheral T-cell lymphoma and leukemia
Maurer B, Nivarthi H, Wingelhofer B, Pham HTT, Schlederer M, Suske T, Grausenburger R, Schiefer AI, Prchal-Murphy M, Chen D, Winkler S, Merkel O, Kornauth C, Hofbauer M, Hochgatterer B, Hoermann G, Hoelbl-Kovacic A, Prochazkova J, Lobello C, Cumaraswamy AA, Latzka J, Kitzwögerer M, Chott A, Janikova A, Pospíšilova Š, Loizou JI, Kubicek S, Valent P, Kolbe T, Grebien F, Kenner L, Gunning PT, Kralovics R, Herling M, Müller M, Rülicke T, Sexl V, Moriggl R. 
Haematologica. 2020;105(2):435-447, available at https://pubmed.ncbi.nlm.nih.gov/31123029/

2019 and earlier

Archive (2004-2019)